Alexandre Buffet

List of Publications by Year
in descending order

18	1,887	623734 14	839539 18
papers	citations	h-index	g-index

18	18	18	2550
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. Cancer Cell, 2013, 23, 739-752.	16.8	606
2	Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Human Molecular Genetics, 2014, 23, 2440-2446.	2.9	316
3	Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications, 2015, 6, 6044.	12.8	153
4	An overview of 20Âyears of genetic studies in pheochromocytoma and paraganglioma. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101416.	4.7	106
5	Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas. Cancer Research, 2018, 78, 1914-1922.	0.9	96
6	Mosaicism inHIF2A-Related Polycythemia-Paraganglioma Syndrome. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E369-E373.	3.6	87
7	Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1109-1118.	3.6	82
8	Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma. Clinical Cancer Research, 2019, 25, 760-770.	7.0	82
9	International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nature Reviews Endocrinology, 2021, 17, 435-444.	9.6	80
10	Identification of a new VHL exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease. Blood, 2018, 132, 469-483.	1.4	70
11	Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma. Journal of Medical Genetics, 2019, 56, 513-520.	3.2	60
12	TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2Î±-Driven Mesenchymal Transition. Cell Reports, 2020, 30, 4551-4566.e7.	6.4	49
13	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
14	Succinate detection using in vivo 1H-MR spectroscopy identifies germline and somatic SDHx mutations in paragangliomas. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1510-1517.	6.4	22
15	Germline mutations in the new E1â€™ cryptic exon of the VHL gene in patients with tumours of von Hippel-Lindau disease spectrum or with paraganglioma. Journal of Medical Genetics, 2020, 57, 752-759.	3.2	12
16	Screening of a Large Cohort of Asymptomatic SDHx Mutation Carriers in Routine Practice. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1301-e1315.	3.6	10
17	Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 459-471.	3.6	6
18	Quantifying evidence toward pathogenicity for rare phenotypes: The case of succinate dehydrogenase genes, SDHB and SDHD. Genetics in Medicine, 2022, 24, 41-50.	2.4	5